Authors: Olaf Schultz, Frank Oberhauser, Jasemine Saech, Andrea Rubbert-Roth, Moritz Hahn, Wilhelm Krone, Matthias Laudes
DOI: 10.1371/journal.pone.0014328
Abstract Summary
Blocking IL-6 signaling with Tocilizumab improved insulin sensitivity in rheumatoid disease patients, suggesting elevated IL-6 may causally contribute to insulin resistance in type 2 diabetes. Treatment increased adiponectin levels and decreased the leptin-to-adiponectin ratio, a marker of insulin resistance, while also reducing lipoprotein(a), potentially lowering cardiovascular risk.
Why Brain? ðŸ§
Blocking IL-6 signaling with Tocilizumab improved insulin sensitivity and reduced cardiovascular risk markers in rheumatoid patients, suggesting IL-6 plays a causal role in diabetes development.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
